Neurológia pre prax 4/2017
The role of B lymphocytes in the pathogenesis of multiple sclerosis is undoubted any more. The research of last years has been recently corroborated by three successful phase III clinical trials with ocrelizumab, a humanized monoclonal antibody against CD20 molecule which is a marker of B lymphocytes. The spectrum of most effective drugs for remitting phase of multiple sclerosis is broadened by a drug with novel mechanism of action. The proof of the effect of this drug in primary progressive multiple sclerosis where no treatment existed up to now represents an important progress.
Keywords: multiple sclerosis, ocrelizumab, primary progression, clinical study, pathogenesis
